Andrew W Roberts
Overview
Explore the profile of Andrew W Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
12566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chua C, Loo S, Fong C, Ting S, Tiong I, Fleming S, et al.
Blood Adv
. 2025 Jan;
PMID: 39825857
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax...
2.
Bennett R, Juneja M, Anderson M, Minson A, Herbert K, Lieschke G, et al.
Leuk Lymphoma
. 2025 Jan;
1-4.
PMID: 39810335
No abstract available.
3.
Peng H, Jabbari J, Tian L, Wang C, You Y, Chua C, et al.
Genome Res
. 2025 Jan;
PMID: 39794120
Single-cell long-read sequencing has transformed our understanding of isoform usage and the mutation heterogeneity between cells. Despite unbiased in-depth analysis, the low sequencing throughput often results in insufficient read coverage,...
4.
Luo M, Tan T, Trussart M, Poch A, Nguyen T, Speed T, et al.
Blood
. 2024 Oct;
144(26):2748-2761.
PMID: 39471335
Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax...
5.
Gao M, Georgiou A, Lin V, Jahja M, White C, Anderson M, et al.
Br J Haematol
. 2024 Jul;
205(4):1389-1394.
PMID: 39031781
Despite significant progress in treating chronic lymphocytic leukaemia (CLL), resistance to therapy remains challenging. NOTCH1 activation, common in CLL, confers adverse prognosis. This study explores the impact of NOTCH1 signalling...
6.
Diepstraten S, Yuan Y, La Marca J, Young S, Chang C, Whelan L, et al.
Cancer Cell
. 2024 Apr;
42(5):850-868.e9.
PMID: 38670091
TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell...
7.
Handunnetti S, Anderson M, Burbury K, Thompson P, Burke G, Bressel M, et al.
Blood
. 2024 Apr;
144(8):867-872.
PMID: 38662991
In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both...
8.
Tiong I, Wall M, Bajel A, Kalro A, Fleming S, Roberts A, et al.
Blood Cancer J
. 2024 Mar;
14(1):54.
PMID: 38531863
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental...
9.
Arnaud A, Schilsky S, Lucia J, Maia M, Laredo F, Marques A, et al.
Clin Appl Thromb Hemost
. 2024 Mar;
30:10760296241241525.
PMID: 38523315
European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics,...
10.
Stilgenbauer S, Tausch E, Roberts A, Davids M, Eichhorst B, Hallek M, et al.
Blood Adv
. 2024 Jan;
8(8):1992-2004.
PMID: 38290108
Chromosome 17p deletion (del[17p]) is associated with poor prognosis in patients with chronic lymphocytic leukemia (CLL). Venetoclax is approved for treatment of previously untreated and relapsed/refractory (R/R) CLL, including patients...